Primerjava kakovosti življenja bolnic po prebolelem raku dojk: ženske iz programa DORA in bolnice iz raziskave OREH : magistrsko delo

Zafran Rojec, Sergeja (avtor), Kurir-Borovčić, Mateja (mentor), Bešić, Nikola (komentor), Žager Marciuš, Valerija (recenzent)

Uvod: Kakovost življenja je večrazsežnostni pojem. Rak dojk in zdravljenje raka dojk ima lahko velik vpliv na kakovost življenja ženske. Namen: Državni presejalni programa za raka dojk DORA je namenjen odkrivanju raka dojk v zgodnjih fazah bolezni in zagotavlja boljšo kakovost življenja za žensko. Namen te raziskave je bil ugotoviti, ali obstaja razlika v kakovosti življenja med bolnicami, ki jim je bil rak diagnosticiran v okviru Državnega presejalnega programa DORA, in ostalimi bolnicami, ki so bile vključene v raziskavo OREH. Metode dela: Raziskava je bila izvedena kot retrospektivno neintervencijska študija s sekundarno analizo podatkov, predhodno pridobljenih z raziskavo OREH. Rezultate smo pridobili z analizo podatkov, pridobljenih s standardiziranim anketnim vprašalnikom EORTC QLQ C-30, ki so vnešeni v sistem RedCAP Onkološkega inštituta Ljubljana. Rezultati: Opravljena je bila statistična analiza vseh skupin (DORA_kontrolna, DORA_interventna, OREH_kontrolna, OREH_interventna). Kot statistično značilno smo dokazali le razliko v kakovosti življenja pred in po zdravljenju, merjeno z vprašanjem Q30 (p = 0,011). Pri večini skupin se zadovoljstvo pred in po zdravljenju največkrat (30 %) ohrani, po zdravljenju pa se poslabša kakovost življenja v OREH_kontrolni skupini. Bolnice v skupinah DORA so imele najpogosteje raka dojke stadija I (71 %), zgolj 4 % pa v višjih stadijih (stadij III in stadij IV), medtem ko so imele bolnice v skupinah OREH največkrat bolezen stadija II (45 %), vendar pa so imele pogosteje višje stadije (stadij III in stadij IV) v primerjavi s skupino DORA. Med kontrolnima skupinama (DORA_kontrolna, OREH_kontrolna) smo ugotovili boljšo kakovost življenja v skupini DORA_kontrolna pred zdravljenjem, merjeno z vprašanjem Q29 (p = 0,038) in vprašanjem Q30 (p = 0,047), po zdravljenju pa razlika več ni bila statistično značilna. Razprava in zaključek: Ugotovili smo, da največ bolnic (30 %) meni, da se jim kakovost življenja ohrani. Bolnice, napotene prek presejalnega programa DORA, imajo boljšo kakovost življenja po prebolelem raku dojk kot ostale bolnice z rakom dojk, vključene v raziskavo OREH. Vzrok za to je verjetno v tem, da je imelo vsaj 70 % žensk, napotenih prek programa DORA, nižji začetni stadij bolezni kot ostale bolnice iz programa OREH.

• Jezik: Slovenski jezik
• Ključne besede: magistrska dela, radiološka tehnologija, mamografija, rak dojk, kakovost življenja, OREH, DORA
• Vrsta gradiva: Magistrsko delo/naloga
• Tipologija: 2.09 - Magistrsko delo
• Organizacija: ZF - Zdravstvena fakulteta
• Kraj izida: Ljubljana
• Založnik: [S. Zafran Rojec]
• Leto izida: 2025
• Št. strani: 43 str., [5] str. pril.
• PID: 20.500.12556/RUL-177179
• UDK: 616-07
• COBISS.SI-ID: 261885699
• Datum objave v RUL: 17.12.2025

Sekundarni jezik

• Jezik: Angleški jezik
• Naslov: Evaluation of quality of life of patients after breast cancer: women from the DORA program with patients who were included in the OREH research (study) : master thesis

Izvleček

Introduction: Quality of life is a multidimensional concept. Breast cancer and its treatment have a major impact on a woman's quality of life. Purpose: The national breast cancer screening program DORA is aimed at detecting breast cancer in the early stages of the disease, which also ensures a better quality of life for women. The purpose of this study was to determine whether there is a difference in quality of life between patients diagnosed with cancer within the National Breast Cancer Screening Program DORA and other patients included in the OREH study. Methods: The study was conducted as a retrospective non-interventional study with a secondary analysis of data previously obtained from the OREH study. The results were obtained by analyzing data obtained with the standardized EORTC QLQ C-30 questionnaire, which are entered into the RedCAP system of the Oncology Institute of Ljubljana. Results: A statistical analysis of all groups was performed (DORA_control, DORA_intervention, OREH_control, OREH_intervention). The only statistically significant difference was the difference in quality of life before and after treatment, measured by question Q30 (p=0.011). In most groups, satisfaction before and after treatment was most often maintained (30%), while after treatment, the quality of life of the OREH_control group worsened. Patients in the DORA groups most often had stage I breast cancer (71%) and only 4% in higher stages (stage III and stage IV), while patients in the OREH groups most often had stage II disease (45%), but they had higher stages more often (stage III and stage IV) compared to the DORA group. Between the control groups (DORA_control, OREH_control), we found better quality of life in the DORA_control group before treatment, measured by question Q29 (p=0.038) and question Q30 (p=0.047), but after treatment the difference was no longer statistically significant. Discussion and conclusion: We found that the largest proportion (30%) of patients believe that their quality of life is preserved. Patients referred through the DORA screening program have a better quality of life after breast cancer than other breast cancer patients included in the OREH study. The reason for this is probably that at least 70% of women referred through the DORA program had a lower initial stage of the disease than other patients from the OREH study.

• Ključne besede: master's theses, radiologic technology, mammography, breast cancer, quality of life, OREH, DORA